对精神分裂症的基于谷氨酸的治疗策略:超越多巴胺的新兴方法
Mihaela Fadgyas-Stanculete1, Octavia Oana Capatina1
1Department of Neurosciences, Discipline of Psychiatry and Pediatric Psychiatry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400394 Cluj-Napoca, Romania.
International journal of molecular sciences
|May 14, 2025
概括
基于谷氨酸的疗法在治疗精神分裂症,特别是认知和负面症状方面表现有前途. 需要进一步的研究来优化这些治疗方法并改善患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 精神分裂症呈现出正面,负面,认知和社会症状.
- 针对多巴胺通路的传统抗精神病药对负面和认知症状的疗效有限.
- 谷氨基基通路调节失调,特别是N-甲基-D-酸盐受体 (NMDA-R) 功能下降,与精神分裂症的病理生理学有关.
研究的目的:
- 审查新兴的基于谷氨酸的精神分裂症治疗策略.
- 总结各种谷氨酸胺调节剂的临床前和临床研究结果.
- 讨论新的干预措施和精神分裂症治疗的未来研究方向.
主要方法:
- 对谷氨酸向治疗的临床前和临床研究的综述.
- 关于NMDA受体调节剂,mGluR剂,谷氨酸转运器调节剂和金氨酸通路抑制剂的机制,疗效和限制的概述.
- 讨论包括神经炎症调节和突触可塑性增强在内的新型干预措施.
主要成果:
- 新兴的基于谷氨酸的策略包括NMDA协激剂,甘氨酸载体抑制剂,D-氨基酸氧化酶抑制剂和mGluR向疗法.
- 这些疗法旨在恢复谷氨酸平衡,解决当前治疗方法的局限性.
- 不一致的临床结果凸显了基于生物标志物的患者选择和优化方案的需要.
结论:
- 谷氨酸调节为精神分裂症提供了一个有前途的治疗途径,特别是在持续的负面和认知症状方面.
- 将谷氨酸调节剂与现有的抗精神病药物相结合可能会提高疗效并减少副作用.
- 未来的研究应该专注于改进干预措施,识别生物标志物和解决疾病异质性.
更多相关视频
相关概念视频
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
311
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
311
01:28Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
01:14Antiepileptic Drugs: Glutamate Antagonists
261
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
261
01:26Psychosis: Goals of Pharmacotherapy
99
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
99
01:28Psychosis and Antipsychotic Drugs: Overview
162
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
162
01:22Alzheimer's Disease: Treatment
134
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
134